Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: -others

A Pseudocowpox virus vector to generate human B cell-based vaccines

C. Thioudellet, et al. CICON 2025 – Download the Poster

Published 7 August 2025
Categorized as -others, 2025, Publication

Utilisation de l’analyseur xCELLigence RTCA eSight pour l’évaluation de la nouvelle plateforme de virus oncolytique de Transgene

B. Moreau et al.AFH 2025Download the poster herePoster presentation

Published 4 July 2025
Categorized as -others, 2025, Publication

A randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic(R/M) HPV16-positive cervical or anogenital cancer

C. Le Tourneau, et al. ASCO 2025 Abstract available on the ASCO website – Download the abstract – Download the Poster

Published 22 May 2025
Categorized as -others, 2025, Publication, TG4001, TG4001

A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer

E. J. West et al.Clinical Cancer Research April 2025Download the publication herePublication

Published 15 April 2025
Categorized as -others, 2025, Publication, TG6002

TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery

J. Foloppe, et al. IOVC 2024  Abstract available on the IOVC website – Download the abstract and the poster

Published 27 October 2024
Categorized as -others, 2024, Invir.IO, Publication

Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity

U. Hirigoyen, et al. Oncology 2024 Article available on the Molecular Therapy Oncology website – Download the Article

Published 24 September 2024
Categorized as -others, 2024, Invir.IO, Publication

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Published 29 August 2023
Categorized as -others, 2023, Publication, TG4001, TG4001

Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy

H. Le et al.AACR 2023Download the poster herePoster Presentation

Published 19 April 2023
Categorized as -others, 2023, Invir.IO, Publication

PoxSTG, a novel chimeric poxvirus with improved oncolytic potency

P Erbs et al.AACR 2023Download the poster herePoster Presentation

Published 19 April 2023
Categorized as -others, 2023, Invir.IO, Publication

A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers

C. Le Tourneau, et al. AACR 2023 – Download the Poster

Published 17 April 2023
Categorized as -others, 2023, Publication, TG4001, TG4001

Posts pagination

Newer posts Page 1 Page 2 … Page 10 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu